Squarepoint
MRNA icon

Squarepoint’s Moderna MRNA Stock Holding History

Squarepoint’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.5M Sell
757,700
-1,851,700
-71% -$86.4M 0.05% 412
2025
Q4 		$77M Sell
2,609,400
-1,931,200
-43% -$52.5M 0.08% 271
2025
Q3 		$117M Buy
4,540,600
+1,478,300
+48% +$41.2M 0.12% 180
2025
Q2 		$84.5M Buy
3,062,300
+2,393,000
+358% +$63M 0.09% 245
2025
Q1 		$19M Sell
669,300
-502,100
-43% -$17.8M 0.02% 714
2024
Q4 		$48.7M Buy
1,171,400
+707,900
+153% +$33.8M 0.05% 386
2024
Q3 		$31M Buy
463,500
+354,800
+326% +$32.6M 0.05% 409
2024
Q2 		$12.9M Sell
108,700
-203,400
-65% -$25.7M 0.02% 804
2024
Q1 		$33.3M Sell
312,100
-5,000
-2% -$504K 0.06% 397
2023
Q4 		$31.5M Sell
317,100
-22,100
-7% -$1.86M 0.06% 374
2023
Q3 		$35M Sell
339,200
-49,200
-13% -$5.49M 0.09% 257
2023
Q2 		$47.2M Buy
388,400
+213,900
+123% +$28.5M 0.14% 142
2023
Q1 		$26.8M Buy
174,500
+104,400
+149% +$17.2M 0.11% 197
2022
Q4 		$12.6M Sell
70,100
-32,400
-32% -$5.3M 0.05% 410
2022
Q3 		$12.1M Buy
102,500
+41,900
+69% +$6.36M 0.06% 362
2022
Q2 		$8.66M Buy
60,600
+37,000
+157% +$5.29M 0.05% 453
2022
Q1 		$4.07M Buy
23,600
+1,800
+8% +$303K 0.02% 809
2021
Q4 		$5.54M Sell
21,800
-29,100
-57% -$8.51M 0.01% 753
2021
Q3 		$19.6M Buy
50,900
+700
+1% +$258K 0.06% 308
2021
Q2 		$11.8M Buy
50,200
+11,800
+31% +$2.11M 0.04% 405
2021
Q1 		$5.03M Buy
+38,400
New +$5.56M 0.03% 631

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's MRNA Position: Q1 2026 in Review

Squarepoint reduced its Moderna (MRNA) stake by 78% in Q1 2026, selling an estimated $35.6M and leaving 212,709 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #1024.

Squarepoint first reported a position in MRNA in Q2 2019 and has held it in 24 quarters since. The position peaked at $37.1M in Q4 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Squarepoint held 212,709 shares of Moderna worth $10.8M as of Q1 2026.
  • Squarepoint sold 762,486 Moderna shares in Q1 2026, an estimated $35.6M.
  • Moderna made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1024 holding.
  • Squarepoint first reported a position in Moderna in Q2 2019 and has held it in 24 quarters since.
  • Squarepoint's Moderna position peaked at $37.1M in Q4 2024.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.